Insulin

SmithRx Continues to Fix Broken Pharmacy Benefits Management System, Closes $60M in Series C Funding Led by Venrock

Retrieved on: 
Tuesday, January 23, 2024
Professional Services, Managed Care, Other Consumer, Health, Women, Pharmaceutical, Men, Insurance, Consumer, Human Resources, Finance, Cost Plus Drugs, Silicon, PBM, Pharmacy, Venrock, Patient, Insulin, Amazon Pharmacy, Pharmaceutical industry

SmithRx , a next-generation pharmacy benefits management (PBM) company, closed a $60M Series C financing round — building on the company’s $20M Series B round raised in 2022.

Key Points: 
  • SmithRx , a next-generation pharmacy benefits management (PBM) company, closed a $60M Series C financing round — building on the company’s $20M Series B round raised in 2022.
  • Led by top Silicon Valley healthcare venture capital firm Venrock , the latest funding positions SmithRx to continue reducing costs of pharmacy benefits for small and midsize self-insured businesses.
  • “Medications in the U.S. cost too much because the overall system is broken,” said Jake Frenz , founder and CEO of SmithRx.
  • “At the core of this broken system are pharmacy benefit managers that drive up the costs.

Napoli Shkolnik 2023 In Review: Law Firm Reaches Groundbreaking Victories for Victims of Water Contamination; Important Litigation Filed in Insulin Pricing Scheme, Air Pollution, and More

Retrieved on: 
Wednesday, January 24, 2024
Legal, Professional Services, Learning, PFAS, UnitedHealth Group, AFFF, Drinking water, Trauma center, Sanofi, City, Injury, Insurance, Curriculum, P.C, Massage, Risk, Corteva, Federation, Insulin, Pharmacy, Eli Lilly and Company, Cancer, Water, 3M, MDL, Class Action, Pregnancy, Atmosphere, Express Scripts, Pain, Ethylene oxide, Plaintiff, Pharmaceutical industry

National law firm Napoli Shkolnik has concluded another successful year of landmark settlements and significant legal action in the areas of environmental litigation, mass tort, and human rights.

Key Points: 
  • National law firm Napoli Shkolnik has concluded another successful year of landmark settlements and significant legal action in the areas of environmental litigation, mass tort, and human rights.
  • Among the firm’s accomplishments of 2023 were significant breakthroughs in the ongoing multidistrict litigation (MDL) against manufacturers of aqueous film-forming foam (AFFF).
  • The funds will go to cities, towns and other public water providers over a 13-year period to test for and treat PFAS contamination.
  • The program’s rigorous and enriching curriculum is designed to continue Napoli Shkolnik’s legacy of delivering justice for their clients.

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, FDA, Pharmaceutical, Health, Entrepreneurship, Obesity, DSM-IV codes, Erythropoietin, Therapy, Facial muscles, Muscular dystrophy, Walking, Orphan drug, Homeostasis, Growth hormone, Drug discovery, Insulin, Disorder, Food, Human, DM1, Protein, Myotonic Dystrophy Foundation, Myotonic dystrophy, Metabolism, Pharmaceutical industry

Juvena Therapeutics , a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161.

Key Points: 
  • Juvena Therapeutics , a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161.
  • JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.
  • “People living with DM1 deserve safe, effective, and rejuvenating treatments that can repair and restore tissue health to improve muscle function and metabolism,” said Dr. Hanadie Yousef, Co-Founder and CEO of Juvena Therapeutics.
  • Additionally, Juvena has identified multiple secreted protein hits that induce disease-modifying effects across several metabolic organs and therapeutic areas.

Four Baron & Budd Shareholders Recognized Among 2024 Lawdragon 500 Leading Lawyers in America

Retrieved on: 
Wednesday, January 17, 2024
Publishing, Communications, Professional Services, Media, Legal, PFAS, ELG, PCB, AFFF, ARC, Drinking water, The Electric Company, Volkswagen, Lawyer, Tellis, History, Professional corporation, Product liability, Court, Water, Hyundai, MDL, Baron, Class Action, Baron & Budd, P.C., Peer review, News, Negotiation, Insulin

The nationally recognized law firm Baron & Budd is pleased to announce that four of the firm’s shareholders have been selected to the 2024 edition of the Lawdragon 500 Leading Lawyers in America.

Key Points: 
  • The nationally recognized law firm Baron & Budd is pleased to announce that four of the firm’s shareholders have been selected to the 2024 edition of the Lawdragon 500 Leading Lawyers in America.
  • Lawdragon is a legal media company that provides online news, editorials, and publishes guides to the nation’s leading lawyers.
  • Since it was founded in 2005, Lawdragon’s 500 Leading Lawyers in America has been established as one of the most prestigious guides in the legal profession.
  • Serving as a Baron & Budd shareholder since 1985 and president and managing shareholder since 2002, Budd presides over one of the nation’s largest plaintiffs’ firms.

GNC Introduces Game Changing Weight Loss Solution Total Lean® GlucaTrim™

Retrieved on: 
Monday, January 22, 2024
Berberine, Meal, Total, Weight loss, Health, Diet, Facial muscles, Insulin, Food, Disease, GNC, PRO, Blood, Metabolism, Dietary supplement

PITTSBURGH, Jan. 22, 2024 /PRNewswire/ -- GNC, the global powerhouse in health and wellness, today announced the debut of GNC Total Lean® GlucaTrim™, the new multi-action weight loss supplement designed to help users drop pounds and lose inches by utilizing an innovative formula that maintains lean muscle mass, while supporting healthy blood sugar and insulin levels. GlucaTrim offers solutions to the issues facing health-conscious consumers interested in weight loss without a prescription.

Key Points: 
  • "GNC Total Lean GlucaTrim gives consumers an affordable, non-prescription, botanical-focused supplement that's backed by a team of scientists and dietitians who are passionate about helping people reach their weight loss goals."
  • Many trending weight loss solutions significantly reduce lean mass and muscle, leaving negative impacts on metabolism and long-term weight loss.
  • The breakthrough formulation used in GlucaTrim is proven to support metabolism in the user's weight loss journey by protecting against the loss of critical muscle mass.
  • The comprehensive range of Total Lean offerings includes the Total Lean meal replacement shakes in both powder and ready-to-drink formats, Lean Bars, and weight management supplements Total Lean 60 Burn and Total Lean CLA.

New Clinical Trial Shows That While The Mediterranean Diet is Good, Pure C15:0 Supplementation Makes It Better

Retrieved on: 
Thursday, January 18, 2024
Fruit, NAFLD, Vegetable, EPA, Health, American Journal, SAN, Diet, Global health, Science, Nut, Fatty liver disease, Insulin, Calorie, LDL, Glucose, Grain boundary strengthening, Liver, Triglyceride, Longevity, Bifidobacterium, Clinical trial, Shellfish, Trial of the century, Blood pressure, Dietary supplement

SAN DIEGO, Jan. 18, 2024 /PRNewswire/ -- A game-changing clinical trial has revealed that enhancing the already renowned Mediterranean diet with pure C15:0 supplementation can elevate health outcomes even further.

Key Points: 
  • In a randomized, double-blinded and controlled clinical trial, supplementation with the same pure C15:0 ingredient in fatty15 improved the health outcomes of the Mediterranean diet.
  • SAN DIEGO, Jan. 18, 2024 /PRNewswire/ -- A game-changing clinical trial has revealed that enhancing the already renowned Mediterranean diet with pure C15:0 supplementation can elevate health outcomes even further.
  • The recent randomized, double-blinded, and controlled clinical trial , published in the American Journal of Clinical Research, has the scientific nutrition community buzzing.
  • Participants were divided into three groups: a caloric-restricted diet, a caloric-restricted diet following Mediterranean diet guidelines, and a caloric-restricted Mediterranean diet with C15:0 supplementation.

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

Retrieved on: 
Monday, January 15, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Diabetes, Clinical Trials, Health Technology, Software, Biotechnology, Health, Data Management, CGM, FIN Atlantic Film Festival, Dexcom, EASD, Associate professor, Partnership, Hypoglycemia, University, Risk, DXCM, Diabetic retinopathy, Insulin, G7, Tandem Diabetes Care, AID, Tandem, University of Nottingham, Medical device

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.
  • The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2.
  • Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the t:slim X2 insulin pump with Control-IQ technology5.
  • To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump, visit Dexcom.co.uk/tandem.

Longer-Term Nut Consumption Improves Brain Insulin Sensitivity, New Study Finds

Retrieved on: 
Tuesday, January 16, 2024
Ageing, Obesity, Notifiable disease, Woman, Research, MRI, American Journal, Maastricht University, Insulin, CBF, LDL, Magnetic resonance imaging, Cholesterol, Overweight

BARCELONA, Spain, Jan. 16, 2024 /PRNewswire/ -- Results from a recent INC-funded intervention study were published in the American Journal of Clinical Nutrition [1]. The study showed that for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved brain insulin sensitivity. This may be important for the prevention of age-related metabolic and cognitive diseases.

Key Points: 
  • The study showed that for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved brain insulin sensitivity.
  • Cerebral blood flow (CBF) was quantified using magnetic resonance imaging (MRI), while brain insulin sensitivity was assessed by measuring regional CBF responses to intranasal insulin.
  • The study found that nut consumption significantly improved insulin action in (occipital and frontal) brain regions involved in the modulation of metabolic and cognitive processes.
  • However, intrahepatic lipid content, serum LDL ('bad') cholesterol and systolic blood pressure were lower following nut consumption compared to the control period.

Longer-Term Nut Consumption Improves Brain Insulin Sensitivity, New Study Finds

Retrieved on: 
Tuesday, January 16, 2024
Ageing, Obesity, Notifiable disease, Woman, Research, MRI, American Journal, Maastricht University, Insulin, CBF, LDL, Magnetic resonance imaging, Cholesterol, Overweight

BARCELONA, Spain, Jan. 16, 2024 /PRNewswire/ -- Results from a recent INC-funded intervention study were published in the American Journal of Clinical Nutrition [1]. The study showed that for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved brain insulin sensitivity. This may be important for the prevention of age-related metabolic and cognitive diseases.

Key Points: 
  • The study showed that for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved brain insulin sensitivity.
  • Cerebral blood flow (CBF) was quantified using magnetic resonance imaging (MRI), while brain insulin sensitivity was assessed by measuring regional CBF responses to intranasal insulin.
  • The study found that nut consumption significantly improved insulin action in (occipital and frontal) brain regions involved in the modulation of metabolic and cognitive processes.
  • However, intrahepatic lipid content, serum LDL ('bad') cholesterol and systolic blood pressure were lower following nut consumption compared to the control period.

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 9, 2024
Diabetes, DSM-IV codes, Patient, Leukemia, CTA, PST, Research, CLL, Osteopathic medicine in Canada, Diagnosis, FLT3, NSCLC, Insulin, Cancer, IND, Conference, Safety, DLBCL, FDA, Glycated hemoglobin, PDAC, AML, CRC, Phase, Health Canada, Week, Pharmaceutical industry

Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024.

Key Points: 
  • Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024.
  • A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events .
  • “2023 was a truly remarkable year for Biomea as we had several positive data readouts in both type 2 diabetes and AML.
  • “We believe BMF-219 has the potential to address the root cause of diabetes and modify its progression in patients.